Imperial College London

Prof. William Wisden F. Med. Sci.

Faculty of Natural SciencesDepartment of Life Sciences

Chair in Molecular Neuroscience
 
 
 
//

Contact

 

+44 (0)20 7594 9744w.wisden Website CV

 
 
//

Location

 

401BSir Ernst Chain BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Korpi:1997,
author = {Korpi, ER and Mattila, MJ and Wisden, W and Luddens, H},
journal = {Ann Med},
pages = {275--282},
title = {GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands},
url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9375983},
volume = {29},
year = {1997}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - The main inhibitory neurotransmitter receptor of the brain, the gamma-aminobutyric acid type A receptor (GABA[A]), mediates the actions of several classes of clinically important drugs, such as benzodiazepines, barbiturates and general anaesthetics. This review summarizes the current knowledge on how classical benzodiazepines and novel nonbenzodiazepine compounds act on the benzodiazepine site of GABA(A) receptors and on their clinical pharmacology related to anxiolytic, sedative, hypnotic and cognitive effects or side-effects. Partial agonism, receptor subtype selectivity and novel binding sites are discussed as possible strategies to develop new drugs with fewer adverse effects than are seen in the clinical use of benzodiazepines.
AU - Korpi,ER
AU - Mattila,MJ
AU - Wisden,W
AU - Luddens,H
EP - 282
PY - 1997///
SN - 0785-3890
SP - 275
TI - GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands
T2 - Ann Med
UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9375983
VL - 29
ER -